Benjamin Jackson CFA
Stock Analyst at Jefferies
(3.31)
# 2,351
Out of 4,408 analysts
82
Total ratings
53.5%
Success rate
7.1%
Average return
Main Sectors:
Stocks Rated by Benjamin Jackson CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: 0DPB Bavarian Nordic A/S | Maintained: Buy | kr 275.00 → kr 280.00 | $184.60 | +51.68% | 2 | May 19, 2026 | |
| EPA: IPN Ipsen S.A. | Maintained: Hold | €117.00 | $156.20 | -25.10% | 2 | May 17, 2026 | |
| SWX: GALD Galderma Group AG | Reiterated: Buy | CHF 190.00 | $172.95 | +9.86% | 29 | Apr 23, 2026 | |
| ZLDPF Zealand Pharma A/S | Maintained: Buy | $78 | $44.70 | +75.33% | 2 | Apr 19, 2026 | |
| SWX: COPN Cosmo N.V. | Maintained: Buy | CHF 150.00 → CHF 140.00 | $71.00 | +97.18% | 2 | Mar 25, 2026 | |
| GMAB Genmab | Initiated Coverage: Buy | $42 | $24.58 | +68.84% | 1 | Feb 17, 2026 | |
| LON: 0MGB Genmab A/S | Initiated Coverage: Buy | kr 2,650 | $1,616.00 | +63.99% | 1 | Feb 16, 2026 | |
| SWX: NOVN Novartis AG | Maintained: Hold | CHF 110.00 | $120.22 | -8.50% | 5 | Feb 4, 2026 | |
| EPA: SAN Sanofi | Maintained: Buy | €100.00 | $75.54 | +32.38% | 9 | Dec 29, 2025 | |
| LON: 0QIU Novo Nordisk A/S | Maintained: Sell | kr 415.00 → kr 290.00 | $287.70 | +0.80% | 7 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | CHF 270.00 → CHF 230.00 | $326.10 | -29.47% | 6 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | 1,450p | $1,958.00 | -25.94% | 2 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | 10,900p | $13,200.00 | -17.42% | 2 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $29 | $38.89 | n/a | 1 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €6.80 | $4.88 | n/a | 10 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $3.8 | $2.80 | n/a | 1 | Oct 7, 2024 |
Bavarian Nordic A/S
May 19, 2026
Maintained: Buy
Price Target: kr 275.00 → kr 280.00
Current: $184.60
Upside: +51.68%
Ipsen S.A.
May 17, 2026
Maintained: Hold
Price Target: €117.00
Current: $156.20
Upside: -25.10%
Galderma Group AG
Apr 23, 2026
Reiterated: Buy
Price Target: CHF 190.00
Current: $172.95
Upside: +9.86%
Zealand Pharma A/S
Apr 19, 2026
Maintained: Buy
Price Target: $78
Current: $44.70
Upside: +75.33%
Cosmo N.V.
Mar 25, 2026
Maintained: Buy
Price Target: CHF 150.00 → CHF 140.00
Current: $71.00
Upside: +97.18%
Genmab
Feb 17, 2026
Initiated Coverage: Buy
Price Target: $42
Current: $24.58
Upside: +68.84%
Genmab A/S
Feb 16, 2026
Initiated Coverage: Buy
Price Target: kr 2,650
Current: $1,616.00
Upside: +63.99%
Novartis AG
Feb 4, 2026
Maintained: Hold
Price Target: CHF 110.00
Current: $120.22
Upside: -8.50%
Sanofi
Dec 29, 2025
Maintained: Buy
Price Target: €100.00
Current: $75.54
Upside: +32.38%
Novo Nordisk A/S
Oct 27, 2025
Maintained: Sell
Price Target: kr 415.00 → kr 290.00
Current: $287.70
Upside: +0.80%
Oct 27, 2025
Downgraded: Sell
Price Target: CHF 270.00 → CHF 230.00
Current: $326.10
Upside: -29.47%
Jul 30, 2025
Maintained: Hold
Price Target: 1,450p
Current: $1,958.00
Upside: -25.94%
Jul 29, 2025
Maintained: Hold
Price Target: 10,900p
Current: $13,200.00
Upside: -17.42%
Jan 31, 2025
Upgraded: Buy
Price Target: $29
Current: $38.89
Upside: n/a
Nov 13, 2024
Maintained: Hold
Price Target: €6.80
Current: $4.88
Upside: n/a
Oct 7, 2024
Downgraded: Hold
Price Target: $3.8
Current: $2.80
Upside: n/a